Considering Genetic Testing in Patients With Prostate Cancer
Leonard G. Gomella, MD, discusses the factors that determine which patients with prostate cancer should undergo genetic testing.
Leonard G. Gomella, MD, professor, chair, Department of Urology, and director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the factors that determine which patients with prostate cancer should undergo genetic testing.
The National Comprehensive Cancer Network (NCCN) guidelines state that any patient with multiple family members who are under the age of 55 with prostate cancer should consider getting genetic testing, says Gomella. Additionally, for patients with a heavy burden of other cancers, such as breast cancer, ovarian cancer, melanoma, or pancreatic cancer in the family, or those with hereditary cancer syndromes, they should also consider testing.
Gomella says the least controversial area in genetic testing currently is for the testing of men who present with metastatic prostate cancer as the disease could be inherited. PARP inhibitors, a new class of drugs, will soon be introduced to this space, a treatment that will be driven by genetic testing results.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
